Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The spread of novel Coronavirus (2019-nCoV) related infection (COVID-19) has led to many
patient presentations in the emergency department for respiratory complaints, with many of
these patients requiring ICU admission and ventilatory support. While COVID-19 patients have
an increased need for supportive care, there is currently no specific treatment directed
against 2019-nCoV. Nitric oxide inhalation has been used as a pulmonary vasodilator and has
been found to have antiviral activity against other coronavirus strains. The primary aim of
this study is to determine whether inhaled NO improves short term respiratory status,
prevents future hospitalization, and improves the clinical course in patients diagnosed with
COVID-19 specifically in the emergency department.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital Department of Anesthesia, MGH